Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Esperion Therapeutics Inc has a consensus price target of $7.19 based on the ratings of 9 analysts. The high is $16 issued by HC Wainwright & Co. on August 12, 2024. The low is $2.5 issued by B of A Securities on June 20, 2024. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Needham on August 13, 2024, August 12, 2024, and June 28, 2024, respectively. With an average price target of $10 between Needham, HC Wainwright & Co., and Needham, there's an implied 461.80% upside for Esperion Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Esperion Therapeutics (NASDAQ:ESPR) was reported by Needham on August 13, 2024. The analyst firm set a price target for $6.00 expecting ESPR to rise to within 12 months (a possible 237.08% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Esperion Therapeutics (NASDAQ:ESPR) was provided by Needham, and Esperion Therapeutics maintained their buy rating.
The last upgrade for Esperion Therapeutics Inc happened on June 15, 2023 when B of A Securities raised their price target to $4. B of A Securities previously had an underperform for Esperion Therapeutics Inc.
The last downgrade for Esperion Therapeutics Inc happened on June 20, 2024 when B of A Securities changed their price target from $2.9 to $2.5 for Esperion Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a maintained with a price target of $8.00 to $6.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.